Clinical trial
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
NCT00495079 · Spectrum Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00495079 |
|---|---|
| Title | Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia |
| Official title | A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (Vincristine Sulfate Liposomes Injection) in Adult Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients With Philadelphia Chromosome-negative ALL Who… |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Collaborators | Parexel Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia (ALL) |
| Intervention type | Drug |
| Interventions | Marqibo® (vincristine sulfate liposomes injection) |
| Enrollment | 65 |
| Start date | May 1, 2007 |
| Primary completion | Aug 8, 2010 |
| Completion | Aug 8, 2010 |
| First posted | Jul 2, 2007 |
| Last update posted | Mar 5, 2021 |
| Countries | Canada, Germany, Israel, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: